In addition to PD-L1, other potential biomarkers including state of the art molecular subtyping, in depth TCR sequencing, somatic mutational density quantification, and identification of T cell-inflamed/non-T cell-inflamed tumor microenvironments using immune gene expression profiling are currently under investigation with promising results [7, 36], highlighting the complexity and dynamic changes of the antitumor immune response [13], with the necessity for combined biomarkers. Here, CD274 is linked to neoplasm.